Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06853925 · ClinicalTrials.gov registry record · NA
Testing a Web-based Intervention for Radioactive Iodine Symptom Management to Improve Health-related Quality of Life Among Differentiated Thyroid Cancer Patients
A NA study of Thyroid Neoplasms, sponsored by Georgetown University.
- Recruiting
- Registry status
- NA
- Development phase
- 88
- Enrollment target
- 1
- Study location
NCT06853925 is a NA study of Thyroid Neoplasms that is actively recruiting participants, run by Georgetown University. The registered enrollment target is 88 participants, below the 827-participant average among 7 other Thyroid Neoplasms trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06853925, a NA study of Thyroid Neoplasms, is actively recruiting participants, sponsored by Georgetown University.
- RECRUITING
- Registry status
- NA
- Development phase
- 88 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if adult patients diagnosed with differentiated thyroid cancer can easily use and benefit from an online tool aimed to provide patients with educational resources and symptom management strategies to improve their quality of life after radioactive iodine (RAI) treatment. The main questions it aims to answer are: 1. Can patients easily use and benefit from the RAI Support intervention? 2. Does RAI Support improve health-related quality of life (overall well-being) compared to usual care? This research will help test better digital tools to support thyroid cancer survivors in managing their health after RAI treatment. Researchers will compare RAI Support to treatment as usual (a publicly available informational website about thyroid cancer) to see if RAI Support works to improve patients' overall well-being. Participants will: 1. Receive access to RAI Support or an informational website (treatment as usual) for four weeks. 2. Use the assigned website once a week for up to four weeks. 3. Complete two online questionnaires (an initial questionnaire and a final questionnaire after four weeks of using the assigned website) about symptoms related to RAI treatment, mood, and confidence in managing symptoms. 4. Complete an optional 60 minute virtual interview about your experiencing using the assigned website.
Conditions Studied
Interventions
- BEHAVIORAL Radioactive Iodine Support (RAI Support)
- OTHER Treatment as Usual (TAU)
Study Locations (1)
District of Columbia
- Georgetown University - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2025-10-02 |
| Est. Completion | 2027-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06853925
The ClinicalTrials.gov registry entry for NCT06853925 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 827-participant average among 7 other Thyroid Neoplasms trials with a reported enrollment target (89% lower). The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thyroid Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Radioactive Iodine Support (RAI Support) is the first listed.
NCT06853925 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.
Frequently Asked Questions
What is clinical trial NCT06853925 about?
NCT06853925 is a clinical study titled "Testing a Web-based Intervention for Radioactive Iodine Symptom Management to Improve Health-related Quality of Life Among Differentiated Thyroid Cancer Patients". The goal of this clinical trial is to learn if adult patients diagnosed with differentiated thyroid cancer can easily use and benefit from an online tool aimed to provide patients with educational resources and symptom management strategies to improve their quality of life after radioactive iodine (...
What is the current status of trial NCT06853925?
This trial is currently recruiting. It is a NA study. The enrollment target is 88 participants. The study started on 2025-10-02. Estimated completion is 2027-02.
What conditions does trial NCT06853925 study?
This clinical trial studies the following conditions: Thyroid Neoplasms.
What interventions are being tested in trial NCT06853925?
The interventions under investigation include: Radioactive Iodine Support (RAI Support) (BEHAVIORAL), Treatment as Usual (TAU) (OTHER).
Who is sponsoring clinical trial NCT06853925?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06853925 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TRAIL Study: Feasibility and Pilot
RECRUITING · NA
-
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
RECRUITING
-
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
RECRUITING
-
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
ACTIVE NOT RECRUITING · Phase 1
-
Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
COMPLETED · Phase 3
-
Electrical Impedance Scanning of Thyroid Nodules Prior to Thyroid Surgery: a Prospective Study
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.